nyuuzyou/wikis huggingface dataset:
Tivantinib (ARQ-197)

==General information==
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.Tivantinib manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
==Patient drug information==
No information available.
==Also known as==
*Code name: ARQ-197
==References==
Category:Drugs
Category:Oral medications
Category:MET inhibitors
Category:Investigational drugs
Tivozanib (Fotivda)

=Mechanism of action=
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.Tivozanib (Fotivda) package insert Tivozanib (Fotivda) package insert (locally hosted backup)Fotivda manufacturer's website
==Diseases for which it is established==
*Renal cell carcinoma
**Clear cell renal cell carcinoma
==Patient drug information==
*Tivozanib (Fotivda) package insert
*Tivozanib (Fotivda) patient drug information (UpToDate)Tivozanib (Fotivda) patient drug information (UpToDate)
==History of changes in FDA indication==
*2021-03-10: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
==History of changes in EMA indication==
*2017-08-24: Initial authorization for first line treatment of adult patients with advanced renal cell carcinoma (RCC). (Based on TIVO-1)
*2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. (Based on TIVO-1)
==Also known as==
*Code name: AV-951
*Brand name: Fotivda
==References==
Category:Drugs
Category:Oral medications
Category:VEGFR inhibitors
Category:Clear cell renal cell carcinoma medications
Category:Renal cell carcinoma medications
Category:EMA approved in 2017
Category:FDA approved in 2021
To do page

This page is a running list of tasks that should be done for HemOnc.org. Contributors can either add additional items to be done here, or come here to look for ways to contribute to the site. Please move things from the "to be done" to the "completed" section once it's been done.
==To be done==
*Add more Example chemotherapy order sets for all regimens
*Update information for all medications in the Drug index, e.g. package insert versions
*Add additional information to Consult topics in hematology and oncology
*Add pre-chemotherapy hepatitis B flowchart
*Add ORR to all non-randomized regimens
*Use Pinger or ExternalLinks extension to check for broken links on pages
==Completed==
*Verify at least one protocol for all RCT-based regimens
*Add additional Factor VIII inhibitor regimens & references to acquired hemophilia page: Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr;121(1):21-35. link to original article
*Provide preceding treatment info for all adjuvant regimens
*Change "ICD-9 codes" to "ICD codes" and include ICD-10 codes
*Break apart multipart regimens across the site (A, then B --> A and B)
*Update Guidelines format for consistency across pages
*Find and replace any "/early" URL
*Disambiguate and link together induction and maintenance/consolidation for Follicular_lymphoma
*Alphabetize and verify regimens & references on Breast cancer page
*Link all randomized trials together
*Update Vesicant & irritant chemotherapy page
*Add HLH-2004 to Hemophagocytic lymphohistiocytosis (HLH) https://europepmc.org/article/MED/16937360
*Update Antiemesis page
*Create a consistent level of evidence header for all non-randomized trials
*Change efficacy to follow the guidelines from "Translating statistical findings into plain English"
*Disambiguate and link together induction and maintenance/consolidation for Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL), Diffuse_large_B-cell_lymphoma, Mantle_cell_lymphoma, and Multiple_myeloma
*Add LUX-Lung 3 and LUX-Lung 6 information to Non-small cell lung cancer https://doi.org/10.1016/S1470-2045%2814%2971173-8/abstract
Category:Null pages
Tocilizumab (Actemra)

==Mechanism of action==
Monoclonal antibody directed against the IL-6 receptor
==Diseases for which it is used==
*Castleman disease
==History of changes in FDA indication==
* 2010-01-08: Initial FDA approval for rheumatoid arthritis
==Also known as==
*Brand name: Actemra
Category:Drugs
Category:Intravenous medications
Category:Anti-IL-6R antibodies
Category:Castleman disease medications
Category:FDA approved in 2010
Tofacitinib (Xeljanz)

=Mechanism of action=
From the NCI Drug Dictionary: An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases.
=History of changes in FDA indication=
Note that this drug does not have an oncology-specific label at this time.
*2012-11-06: Initial FDA approval for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
=Also known as=
*Code name: CP-690550
*Generic name: tasocitinib
*Brand name: Xeljanz
Category:Drugs
Category:Oral medications
Category:JAK1 inhibitors
Category:JAK3 inhibitors
Category:FDA approved in 2012
Toremifene (Fareston)

==General information==
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.Toremifene (Fareston) package insertToremifene (Fareston) package insert (locally hosted backup)Fareston manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
*Breast cancer
==Patient drug information==
*Toremifene (Fareston) patient drug information (Chemocare)Toremifene (Fareston) patient drug information (Chemocare)
*Toremifene (Fareston) patient drug information (UpToDate)Toremifene (Fareston) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1997-05-29: Initial approval for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. (Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhönen et al. 1997)
==History of changes in EMA indication==
*1996-02-14: Initial authorization
*Indicated as first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.
==Also known as==
*Brand names: Acapodene, Fareston, Farestone
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:Selective estrogen receptor modulators
Category:Breast cancer medications
Category:EMA approved in 1996
Category:FDA approved in 1997
Toripalimab (Loqtorzi)

==Mechanism of action==
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
==Diseases for which it is established==
*Nasopharyngeal carcinoma
==Diseases for which it is used==
*Breast cancer, triple negative
*Clear cell renal cell carcinoma
*Esophageal squamous cell carcinoma
*Melanoma
*Non-small cell lung cancer, nonsquamous
*Non-small cell lung cancer, squamous
*Urothelial carcinoma
==History of changes in FDA indication==
*2023-10-27: Approved with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). (Based on JUPITER-02)
*2023-10-27: Approved as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. (Based on POLARIS-02)
==History of changes in NMPA indication==
*2018-12-17: Initial approval
*2024-04-11: Approved in combination with axitinib for the first-line treatment of patients with medium- to high-risk unresectable or metastatic renal cell carcinoma (RCC). (Based on RENOTORCH)
==Also known as==
*Code names: JS-001, TAB-001
*Generic name: teriprolizumab, toripalimab-tpzi
*Brand name: Loqtorzi, Tuoyi
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1 antibodies
Category:Breast cancer medications
Category:Esophageal squamous cell carcinoma medications
Category:Melanoma medications
Category:Nasopharyngeal carcinoma medications
Category:Non-small cell lung cancer, nonsquamous medications
Category:Non-small cell lung cancer, squamous medications
Category:Urothelial carcinoma medications
Category:NMPA approved in 2018
Category:FDA approved in 2023
Tosedostat (CHR-2797)

==Mechanism of action==
From the NCI Drug Dictionary: A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Tosedostat is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid deprivation, inhibition of protein synthesis due to a decrease in the intracellular free amino acid pool, an increase in the level of the proapoptotic protein Noxa, and cell death. Noxa is a member of the BH3 (Bcl-2 homology 3)-only subgroup of the proapoptotic Bcl-2 (B-cell CLL/lymphoma 2) protein family.
==Preliminary Results==
===Acute myeloid leukemia===
# OPAL: Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr;14(4):354-62. Epub 2013 Feb 28. link to original article link to PMC article EuroPMC
# Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. Br J Haematol. 2016 Jan;172(2):238-45. Epub 2015 Nov 16. link to original article EuroPMC
==Also known as==
*Code name: CHR-2797
Category:Drugs
Category:Oral medications
Category:Aminopeptidase inhibitor
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs
Tositumomab and I-131 (Bexxar)

Note: GlaxoSmithKline has discontinued the manufacture and sale of the BEXXAR therapeutic regimen (tositumomab and iodine I 131 tositumomab) as of February 2014.
==General information==
Class/mechanism: Radioimmunotherapy; treatment regimen that includes two separate steps: first, a dosimetric dose with an anti-CD20 antibody (tositumomab) alone, and second, a therapeutic dose with tositumomab bound to a radioactive isotope, iodone-131 (I-131). Tositumomab binds to the extracellular domain of the CD20 molecule expressed on B-cells and may induce complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC). The I-131 that is bound to tositumomab emits ionizing radiation, leading to cell death.Tositumomab and I-131 (Bexxar) package insertTositumomab and I-131 (Bexxar) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it was used==
*Follicular lymphoma
*Indolent lymphoma
*Transformed lymphoma
==Patient drug information==
*Tositumomab and I-131 (Bexxar) patient drug information (Chemocare)Tositumomab and I-131 (Bexxar) patient drug information (Chemocare)
*Tositumomab and I-131 (Bexxar) patient drug information (UpToDate)Tositumomab and I-131 (Bexxar) patient drug information (UpToDate)
==History of changes in FDA indication - PARTIALLY WITHDRAWN==
*2003-06-27: Granted accelerated approval for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab (Rituxan) and has relapsed following chemotherapy. (Based on CP-97-012 & RIT-II-004)
*2004-12-22: Accelerated approval for patients with relapsed or refractory, low grade, follicular or transformed CD20 positive non-Hodgkin's lymphoma who have not received Rituximab (Rituxan). (No supporting studies are cited)
**2013-10-23: Accelerated approval for rituximab-naive patients withdrawn. (failure to complete confirmatory study)
==Also known as==
*Generic names: tositumomab and I 131 tositumomab, tositumomab and iodine-131 tositumomab
*Brand name: Bexxar
==References==
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-CD20 radioimmunoconjugates
Category:Radiotherapy medications
Category:Follicular lymphoma medications (historic)
Category:Indolent lymphoma medications (historic)
Category:Transformed lymphoma medications (historic)
Category:FDA approved in 2003
Category:FDA withdrawn in 2013
Tovorafenib (Ojemda)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth.
==Diseases for which it is used==
*Low-grade glioma, pediatric
==History of changes in FDA indication==
*2024-04-23: Granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. (Based on FIREFLY-1)
==Also known as==
*Code names: BIIB-024, DAY-101, MLN-2480, TAK-580
*Brand name: Ojemda
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:Low-grade glioma, pediatric medications
Category:BRAF inhibitors
Category:RAF1 inhibitors
Category:FDA approved in 2024
Trabectedin (Yondelis)

==General information==
Class/mechanism: Alkylator, binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.Trabectedin (Yondelis) package insertTrabectedin (Yondelis) package insert (locally hosted backup)Yondelis manufacturer's website
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Leiomyosarcoma
*Liposarcoma
*Ovarian cancer
*Soft tissue sarcoma
==Patient drug information==
*Trabectedin (Yondelis) package insert
*Trabectedin (Yondelis) patient drug information from manufacturerTrabectedin (Yondelis) patient drug information from manufacturer
*Trabectedin (Yondelis) patient drug information (Chemocare)Trabectedin (Yondelis) patient drug information (Chemocare)
*Trabectedin (Yondelis) patient drug information (UpToDate)Trabectedin (Yondelis) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2015-10-23: Approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. (Based on ET743-SAR-3007)
==History of changes in EMA indication==
*2007-09-17: Initial authorization
==History of changes in Health Canada indication==
*2010-05-13: Initial notice of compliance
==History of changes in PMDA indication==
*2015-09-28: Initial approval for the treatment of patients with soft tissue sarcoma.
==Also known as==
*Code name: ET-743
*Brand name: Yondelis
==References==
Category:Drugs
Category:Intravenous medications
Category:Vesicant
Category:Alkylating agents
Category:Leiomyosarcoma medications
Category:Liposarcoma medications
Category:Ovarian cancer medications
Category:Soft tissue sarcoma medications
Category:EMA approved in 2007
Category:FDA approved in 2015
Category:Health Canada approved in 2010
Category:PMDA approved in 2015
Tranexamic acid (Cyklokapron)

==Mechanism of action==
Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher
concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. 
==Diseases for which it is used==
*Hereditary hemorrhagic telangiectasia
==History of changes in FDA indication==
*1986-12-30: Initial FDA approval
*2008-12-22 (oldest label available at Drugs @ FDA): Indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. 
==Also known as==
*Brand names: Amixam, Cyklokapron, Hemostan, Prexam, Temsy, Tranofast
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Hemostasis medications
Category:Fibrinolysis inhibitors
Category:Hereditary hemorrhagic telangiectasia medications
Category:FDA approved in 1986
Transplant conditioning regimens

This is an obsolete page; please follow the links below to find the page you're looking for.
=Stem cell mobilization=
=Autologous stem cell transplant=
=Allogeneic hematopoietic cell transplant, myeloablative=
=Allogeneic hematopoietic cell transplant, reduced-intensity conditioning (RIC)=
Category:Obsolete pages
Trastuzumab-anns (Kanjinti)

Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2019-06-13: Initial approval for the treatment of HER2 overexpressing breast cancer.
*2019-06-13: Initial approval for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
==Also known as==
*Brand name: Kanjinti
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2019
Category:Biosimilars
Category:WHO Essential Cancer Medicine
Trastuzumab-dkst (Ogivri)

Note: this is the second FDA-approved biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
==General information==
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is established==
*HER2+ breast cancer
*HER2+ esophageal cancer
*HER2+ gastric cancer
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2017-12-01: Initial approval for the treatment of patients with HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). (Based on HERITAGE)
==Also known as==
*Brand name: Ogivri
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-HER2 antibodies
Category:Neutral
Category:Breast cancer medications
Category:Esophageal cancer medications
Category:Gastric cancer medications
Category:FDA approved in 2017
Category:Biosimilars
Category:WHO Essential Cancer Medicine